Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Alessio FiascarelliGiuseppe MerlinoStefania CapanoSimone TalucciDiego BisignanoAlessandro BressanDaniela BellarosaCorrado CarrisiAlessandro PaoliMario BigioniPatrizia TuniciClelia IrrissutoMassimiliano SalernoJoaquin ArribasElisa de StanchinaMaurizio ScaltritiMonica BinaschiPublished in: Breast cancer research and treatment (2023)
The profile of MEN1611 and its antitumoral activity suggest an improved profile as compared to pan-inhibitors, which are limited by a less than ideal safety profile, and isoform selective molecules, which may potentially promote development of resistance mechanisms. The compelling antitumor activity in combination with trastuzumab in HER2 + trastuzumab-resistant, PIK3CA mutated breast cancer models is at the basis of the ongoing B-Precise clinical trial (NCT03767335).